Brussels (Belgium), 22 November 2011 - 07.30 AM (CET) - UCB has acquired Lectus Therapeutics's key pharmaceutical assets today via a licence and acquisition agreement. Lectus Therapeutics Ltd is a drug discovery and development company focusing on next-generation ion channel modulators. The transaction involves the acquisition of all the company's drug discovery and development programmes targeting ion channels for the treatment of a specific set of CNS indications (Central Nervous System). Financial details of the transaction were not disclosed.
Under the terms of the agreement UCB will also gain exclusive worldwide rights to commercialise products discovered from the use of Lectus's proprietary LEPTICS® technology for a number of further ion channel targets.
The drug discovery and development programmes acquired by UCB centre on the use of Lectus's proprietary LEPTICS® technology to identify compounds in a new area of chemical space. Such compounds are anticipated to possess a novel mechanism of action mediated through an effect on ion channel accessory proteins.
"UCB New Medicines™ is deploying a wide range of innovative and proprietary science and technologies in its search for breakthrough medicines. Lectus's drug discovery and development programmes supports our research efforts in the CNS field. I feel confident it will enable us to further honour our commitment to deliver cutting-edge scientific research driven by the patient's needs.", says Ismail Kola, President of UCB New Medicines™.
Dr Roland Kozlowski, CEO of Lectus, commented: "We are pleased to close this transaction with UCB and anticipate that the competitive edge LEPTICS® brings, together with the enthusiasm and expertise of UCB's team, will lead to success in this challenging area of research and development. This deal executed with one of the leading global biopharmaceutical companies highlights the potential of Lectus's approach to ion channel drug discovery and the value of its LEPTICS® technology."
For further information
Antje Witte, Investor Relations, UCB
T +32.2.559.94.14, antje.witte@ucb.com
France Nivelle, Global Communications, UCB
T: +32.2.559.91.78, france.nivelle@ucb.com
Notes to the editor
About Lectus Therapeutics and LEPTICS®
Lectus Therapeutics is an emerging UK-based drug-discovery
and development company, incorporated in December 2002,
specialising in the discovery and development of novel
drugs for pain management and associated disorders. Lectus
exploits the power of its proprietary functional proteomics
platform, LEPTICS® (Leveraged Enabling Proteomics
Technology for Ion Channel Screening), and builds on its
knowledge of ion channels, to develop novel ion channel
modulators that have the potential to offer important
clinical and economic advantages over existing therapies.
For further information go to . www.lectustherapeutics.com
About UCB
UCB, Brussels, Belgium ( ) is a global biopharmaceutical
company focused on the discovery and development of
innovative medicines and solutions to transform the lives
of people living with severe diseases of the immune system
or of the central nervous system. With more than 8,000
people in about 40 countries, the company generated revenue
of EUR 3.2 billion in 2010. UCB is listed on Euronext
Brussels (symbol: UCB). www.ucb.com
UCB Forward-Looking Statements
This press release contains forward-looking statements
based on current plans, estimates and beliefs of
management. All statements, other than statements of
historical fact, are statements that could be deemed
forward-looking statements, including estimates of
revenues, operating margins, capital expenditures, cash,
other financial information, expected legal, political,
regulatory or clinical results and other such estimates and
results. By their nature, such forward-looking statements
are not guarantees of future performance and are subject to
risks, uncertainties and assumptions which could cause
actual results to differ materially from those that may be
implied by such forward-looking statements contained in
this press release. Important factors that could result in
such differences include: changes in general economic,
business and competitive conditions, the inability to
obtain necessary regulatory approvals or to obtain them on
acceptable terms, costs associated with research and
development, changes in the prospects for products in the
pipeline or under development by UCB, effects of future
judicial decisions or governmental investigations, product
liability claims, challenges to patent protection for
products or product candidates, changes in laws or
regulations, exchange rate fluctuations, changes or
uncertainties in tax laws or the administration of such
laws and hiring and retention of its employees. UCB is
providing this information as of the date of this press
release and expressly disclaims any duty to update any
information contained in this press release, either to
confirm the actual results or to report a change in its
expectations.
There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.
Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.